Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Angiotensin II and pulmonary fibrosis, a new twist on an old story.

Literature DB >> 21724862

Angiotensin II and pulmonary fibrosis, a new twist on an old story.

G R Scott Budinger¹.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2011 PMID： 21724862 PMCID： PMC3174738 DOI： 10.1152/ajplung.00214.2011

Source DB: PubMed Journal: Am J Physiol Lung Cell Mol Physiol ISSN： 1040-0605 Impact factor: 5.464

× No keyword cloud information.

19 in total

1. Transforming growth factor (TGF)-beta1 stimulates pulmonary fibrosis and inflammation via a Bax-dependent, bid-activated pathway that involves matrix metalloproteinase-12.

Authors: Hye-Ryun Kang; Soo Jung Cho; Chun Geun Lee; Robert J Homer; Jack A Elias
Journal: J Biol Chem Date: 2007-01-05 Impact factor: 5.157

Review 2. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy.

Authors: Michael Bader
Journal: Annu Rev Pharmacol Toxicol Date: 2010 Impact factor: 13.820

3. Challenges in translating preclinical studies to effective drug therapies in idiopathic pulmonary fibrosis.

Authors: Victor J Thannickal; Jesse Roman
Journal: Am J Respir Crit Care Med Date: 2010-03-15 Impact factor: 21.405

4. Bleomycin induces alveolar epithelial cell death through JNK-dependent activation of the mitochondrial death pathway.

Authors: Vivian Y Lee; Clara Schroedl; Joslyn K Brunelle; Leonard J Buccellato; Ozkan I Akinci; Hideaki Kaneto; Colleen Snyder; James Eisenbart; G R Scott Budinger; Navdeep S Chandel
Journal: Am J Physiol Lung Cell Mol Physiol Date: 2005-10 Impact factor: 5.464

5. Epithelium-specific deletion of TGF-β receptor type II protects mice from bleomycin-induced pulmonary fibrosis.

Authors: Min Li; Manda Sai Krishnaveni; Changgong Li; Beiyun Zhou; Yiming Xing; Agnes Banfalvi; Aimin Li; Vincent Lombardi; Omid Akbari; Zea Borok; Parviz Minoo
Journal: J Clin Invest Date: 2010-12-06 Impact factor: 14.808

Review 6. Murine models of pulmonary fibrosis.

Authors: Bethany B Moore; Cory M Hogaboam
Journal: Am J Physiol Lung Cell Mol Physiol Date: 2007-11-09 Impact factor: 5.464

7. Proapoptotic Bid is required for pulmonary fibrosis.

Authors: G R Scott Budinger; Gökhan M Mutlu; James Eisenbart; Alyson C Fuller; Amy A Bellmeyer; Christina M Baker; Mindy Wilson; Karen Ridge; Terrence A Barrett; Vivian Y Lee; Navdeep S Chandel
Journal: Proc Natl Acad Sci U S A Date: 2006-03-14 Impact factor: 11.205

Angiotensin II and pulmonary fibrosis, a new twist on an old story.

1. Transforming growth factor (TGF)-beta1 stimulates pulmonary fibrosis and inflammation via a Bax-dependent, bid-activated pathway that involves matrix metalloproteinase-12.

Review 2. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy.

3. Challenges in translating preclinical studies to effective drug therapies in idiopathic pulmonary fibrosis.

4. Bleomycin induces alveolar epithelial cell death through JNK-dependent activation of the mitochondrial death pathway.

5. Epithelium-specific deletion of TGF-β receptor type II protects mice from bleomycin-induced pulmonary fibrosis.

Review 6. Murine models of pulmonary fibrosis.

7. Proapoptotic Bid is required for pulmonary fibrosis.

8. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis.

Review 9. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

10. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis.

1. Angiotensin II: tapping the cell cycle machinery to kill endothelial cells.

2. A review of current and novel therapies for idiopathic pulmonary fibrosis.